系统性硬化症相关肺动脉高压患者生存改善:约翰霍普金斯登记研究
该研究基于约翰霍普金斯肺动脉高压中心登记,比较1999-2010与2010-2021两个十年诊断的504例系统性硬化症相关肺动脉高压(SSc-PH)患者。第1组患者在新近十年诊断时临床和血流动力学特征更优,更常接受初始联合肺动脉高压治疗,无移植生存期延长近4年;第2、3组患者无改善。
要点
- 第1组SSc-PH患者近十年无移植生存期较前十年延长近4年。
- 第1组患者更常接受初始联合肺动脉高压治疗且诊断时特征更优。
- 第2组和第3组SSc-PH患者两个十年间基线特征和生存均无差异。
核心结论
- 第1组SSc-PH患者近十年无移植生存期显著改善,可能源于更早发现和更好的治疗管理。
- 第2组或第3组SSc-PH患者预后仍然不佳,两个十年间无改善。
研究设计与样本
- 前瞻性队列研究,纳入约翰霍普金斯肺动脉高压中心登记的504例SSc-PH患者。
- 按诊断性右心导管日期分为队列A(1999-2010年诊断)和队列B(2010-2021年诊断)。
主要发现
- 504例SSc-PH患者中,308例(61%)为第1组,43例(9%)为第2组,151例(30%)为第3组。
- 队列B第1组患者诊断时临床和血流动力学特征显著更优,更常接受初始联合肺动脉高压治疗。
- 单变量分析中,队列B第1组患者中位无移植生存期较队列A增加近4年(P < 0.01)。
- 调整基线特征后,第1组患者无移植生存期改善仍存在。
- 第2组或第3组患者两个队列间基线临床、血流动力学或生存特征均无差异。
临床怎么用
- 对SSc-PH患者应早期识别并评估第1组疾病,以争取初始联合治疗并改善生存。
- 第2组或第3组SSc-PH患者预后仍差,需关注并探索更有效管理策略。
局限性
- 单中心研究,结果外推需谨慎。
- 原文未报告多变量分析的具体校正变量和效应值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: To date, it remains unclear whether recent changes in the management of patients with systemic sclerosis-associated pulmonary hypertension (SSc-PH) have improved survival. Objectives: To describe a cohort of patients with SSc-PH and compare their characteristics and survival between the last two decades. Methods: Patients with SSc-PH prospectively enrolled in the Johns Hopkins Pulmonary Hypertension Center Registry were grouped into two cohorts based on the date of diagnostic right heart catheterization: cohort A included patients whose disease was diagnosed between 1999 and 2010, and cohort B included those whose disease was diagnosed between 2010 and 2021. Patients' characteristics were compared between the two cohorts. Measurements and Main Results: Of 504 patients with SSc-PH distributed almost equally between the two cohorts, 308 (61%) had World Symposium on Pulmonary Hypertension group 1, 43 (9%) had group 2, and 151 (30%) had group 3 disease. Patients with group 1 disease in cohort B had significantly better clinical and hemodynamic characteristics at diagnosis, were more likely to receive upfront combination pulmonary arterial hypertension therapy, and had a nearly 4-year increase in median transplant-free survival in univariable analysis than those in cohort A (P < 0.01). Improved transplant-free survival was still observed after adjusting for patients' baseline characteristics. In contrast, for group 2 or 3 patients with SSc-PH, there were no differences in baseline clinical, hemodynamic, or survival characteristics between the two cohorts. Conclusions: This is the largest single-center study that compares clinical characteristics of patients with SSc-PH between the last two decades. Transplant-free survival has improved significantly for those with group 1 disease over the last decade, possibly secondary to earlier detection and better therapeutic management. Conversely, those with group 2 or 3 disease continue to have dismal prognosis.
引用
- Hassan HJ, Naranjo M, Ayoub N, et al. Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. Am J Respir Crit Care Med. 2023. PMID: 36173815. doi:10.1164/rccm.202204-0731OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。